Evidence map›Paper›PMID 37668704›Full record

Observational studyJournal of neurology2023

Predictors for progression in amyotrophic lateral sclerosis associated to SOD1 mutation: insight from two population-based registries.

Ilaria Martinelli, Andrea Ghezzi, Elisabetta Zucchi, Giulia Gianferrari, Laura Ferri, Cristina Moglia, Umberto Manera, Luca Solero, Rosario Vasta, Antonio Canosa and 11 more

Open access · greenAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Tofersen for SOD1 ALS.Neurodegenerative disease management · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 2 countries.

Ilaria MartinelliDepartment of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy.
Andrea GhezziDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Elisabetta ZucchiDepartment of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy. elibettizucchi@gmail.com.ORCID http://orcid.org/0000-0001-5604-4529
Giulia GianferrariDepartment of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy.
Laura FerriDepartment of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy.
Cristina MogliaDepartment of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
Umberto ManeraDepartment of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
Luca SoleroDepartment of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
Rosario VastaDepartment of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
Antonio CanosaDepartment of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
Maurizio GrassanoDepartment of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
Maura BrunettiSC Neurologia 1U, AOU Città della Salute e della Scienza of Torino, Turin, Italy.
Letizia MazziniNeurology Unit, ALS Center, AOU Maggiore della Carità and University of Piemonte Orientale, Novara, Italy.
Fabiola De MarchiNeurology Unit, ALS Center, AOU Maggiore della Carità and University of Piemonte Orientale, Novara, Italy.
Cecilia SimoniniDepartment of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy.
Nicola FiniDepartment of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy.
Marco VincetiDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Marcello PintiDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Adriano ChiòDepartment of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
Andrea CalvoDepartment of Neuroscience "Rita Levi Montalcini", ALS Centre, University of Torino, Turin, Italy.
Jessica MandrioliDepartment of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Viale Pietro Giardini, 1355, 41126, Modena, Italy.
University of Modena and Reggio Emilia · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITUniversity of Turin · ITAzienda Ospedaliero-Universitaria di Modena · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITBoston University · US

Funding

Ministero della Salute RF-2016-02362405Ministero dell'Istruzione, dell'Università e della Ricerca 101017598Ministero dell'Istruzione, dell'Università e della Ricerca 2017SNW5MBSeventh Framework Programme 259867
6 · The paper itself

Abstract

backgroundUncovering distinct features and trajectories of amyotrophic lateral sclerosis (ALS) associated with SOD1 mutations (SOD1-ALS) can provide valuable insights for patient' counseling and stratification for trials, and interventions timing. Our study aims to pinpoint distinct clinical characteristics of SOD1-ALS by delving into genotype-phenotype correlations and factors that potentially impact disease progression.

methodsThis is a retrospective observational study of a SOD1-ALS cohort from two Italian registers situated in the regions of Emilia-Romagna, Piedmont and Valle d'Aosta.

resultsOut of 2204 genotyped ALS patients, 2.5% carried SOD1 mutations, with a M:F ratio of 0.83. SOD1-ALS patients were younger, and more frequently reported a family history of ALS and/or FTD. SOD1-ALS had a longer survival compared to patients without ALS-associated gene mutations. However, here was considerable variability in survival across distinct SOD1 mutations, with an average survival of less than a year for the L39V, G42S, G73S, D91N mutations. Among SOD1-ALS, multivariate analysis showed that, alongside established clinical prognostic factors such as advanced age at onset and high progression rate at diagnosis, mutations located in exon 2 or within highly conserved gene positions predicted worse survival. Conversely, among comorbidities, cancer history was independently associated with longer survival.

interpretationWithin the context of an overall slower disease, SOD1-ALS exhibits some degree of heterogeneity linked to the considerable genetic diversity arising from the multitude of potential mutations sites and specific clinical prognostic factors, including cancer history. Revealing the factors that modulate the phenotypic heterogeneity of SOD1-ALS could prove advantageous in improving the efficacy of upcoming therapeutic approaches.

Indexed as

Amyotrophic Lateral SclerosisNeoplasmsHumansMutationRegistriesSuperoxide DismutaseSuperoxide Dismutase-1SOD1 protein, humanSuperoxide DismutaseSuperoxide Dismutase-1ALSAmyotrophic lateral sclerosisGenotype–phenotypePopulation-based registerPrognostic factorsSOD1

Identifiers

PMID37668704
OpenAlexW4386438093

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.